Company intelligence / Profile preview
EOM Pharmaceutical Holdings, Inc.
Montvale, New Jersey, United Stateseompharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has two main pipeline assets: EOM613, a peptide-nucleic acid solution with dual-acting immunomodulatory effects currently in clinical trials for COVID-19 and planned for cancer cachexia and rheumatoid arthritis; and EOM147, a reformulated aminosterol for retinal diseases administered as eye drops rather than intraocular injections.
- Therapeutic areas
- OncologyOphthalmologyImmunologyInfectious Diseases
- Modalities
- Peptide-nucleic acid solutionsAminosterols
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on EOM Pharmaceutical Holdings, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EOM Pharmaceutical Holdings, Inc..